Behçet and LDH/Albumin
A Convenient Parameter for Predicting Behçet's Disease Severity: Lactate Dehydrogenase/Albumin Ratio
1 other identifier
observational
1
1 country
1
Brief Summary
ABSTRACT Objective: To investigate whether the lactate dehydrogenase to albumin ratio can be used as a parameter to determine disease severity in Behçet's disease, an inflammatory disease, by comparing it to healthy controls. Patients and Methods: In this retrospective cohort study, patients with Behçet's disease aged 18-69 years who presented to the outpatient clinic between February 2020 and April 2023 and healthy individuals of similar age and gender were enrolled. LDH, albumin levels, and LDH/albumin ratio of both groups were compared. Clinical findings and characteristics of Behçet's patients and disease severity were recorded and analyzed in relation to LDH/albumin ratio.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2023
CompletedFirst Submitted
Initial submission to the registry
February 18, 2024
CompletedFirst Posted
Study publicly available on registry
February 26, 2024
CompletedFebruary 26, 2024
February 1, 2024
3.2 years
February 18, 2024
February 18, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
LDH/albumin ratio
February 2020 and April 2023
Study Arms (2)
Behçet's Disease
healthy individuals
Interventions
LDH/Albumin ratios of patient and control groups were recorded.
Eligibility Criteria
A total of 349 subjects, including 160 patients with Behçet's disease and 189 healthy controls
You may qualify if:
- Patients with Behçet's disease aged 18-69
You may not qualify if:
- younger than 18 years or older than 69 years, pregnant and lactating patients, patients with acute infection on admission or nutritional problems, symptomatic gastrointestinal symptoms, malignancy, hepatitis or liver disease were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Erdal Pala
Erzurum, 25240, Turkey (Türkiye)
Related Publications (1)
Pala E, Bayraktar M. Lactate dehydrogenase to albumin ratio as a convenient parameter for predicting the severity of Behcet disease: a cross-sectional study. BMC Immunol. 2026 Jan 7;27(1):1. doi: 10.1186/s12865-025-00706-7.
PMID: 41501648DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Skin and Venereal Diseases
Study Record Dates
First Submitted
February 18, 2024
First Posted
February 26, 2024
Study Start
February 1, 2020
Primary Completion
April 1, 2023
Study Completion
April 1, 2023
Last Updated
February 26, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share